Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Core Viewpoint - Nutriband Inc. has received a new patent for its AVERSA™ transdermal abuse deterrent technology, enhancing its intellectual property protection in the United States and internationally, which is crucial for the development of its lead product, an abuse-deterrent fentanyl patch [1][2][3]. Group 1: Patent and Technology - The United States Patent and Trademark Office issued patent number 12,318,492 for "Abuse and Misuse Deterrent Transdermal Systems" on June 3, 2025, expanding Nutriband's intellectual property protection [1]. - AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, misuse, and accidental exposure of drugs with abuse potential, improving the safety profile of transdermal drugs like fentanyl [3][4]. Group 2: Market Potential - Nutriband's lead product under development, Aversa™ Fentanyl, is projected to achieve peak annual U.S. sales between $80 million and $200 million, positioning it as a potential market leader in abuse-deterrent pain patches [2].